Lesson plan
Mylan
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US. In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, the company grew from the third-largest generic and specialty pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan went public on the OTC market in February 1973. It was listed on the NASDAQ, and its shares were a component of the NASDAQ Biotechnology and the S&P 500 indices. The company was founded in 1961 and developed and produced medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare.
Article summary
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US. In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, the company grew from the third-largest generic and specialty pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan went public on the OTC market in February 1973. It was listed on the NASDAQ, and its shares were a component of the NASDAQ Biotechnology and the S&P 500 indices. The company was founded in 1961 and developed and produced medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare.
Key claims
- date of foundation: 1961 — source: Wikipedia · confidence 0.95
- date of foundation: 1961 — source: Wikipedia · confidence 0.95
- date of foundation: 1961 — source: Wikipedia · confidence 0.95
- date of foundation: 1961 — source: Wikipedia · confidence 0.95
- publication date: 2017-06-12 — source: Wikipedia · confidence 0.95
- release date: 2017-05-30 — source: Wikipedia · confidence 0.95
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- The record states that the date of foundation is "1961". What evidence would count against this claim?
- The record states that the date of foundation is "1961". What evidence would count against this claim?
- The record states that the date of foundation is "1961". What evidence would count against this claim?
- The record states that the date of foundation is "1961". What evidence would count against this claim?
- The record states that the publication date is "2017-06-12". What evidence would count against this claim?
- The record states that the release date is "2017-05-30". What evidence would count against this claim?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
- Wikipedia https://en.wikipedia.org/w/index.php?oldid=1378436100
Key claims and bibliography are generated from the same tracked claims and sources as the article page.